Intersect Ent - XENT STOCK NEWS

Intersect ENT, Inc. (Nasdaq: XENT) has announced a change in the date for its first quarter 2021 financial results announcement and conference call. The results will now be released on May 10, 2021, at 7:00 a.m. ET, followed by a conference call at 8:30 a.m. ET. Interested parties can access the call via the internet or by phone. The company continues to focus on transforming patient care through its innovative steroid-releasing implants and recently expanded its product portfolio with the acquisition of Fiagon AG Medical Technologies, enhancing its offerings in surgical navigation.

Intersect ENT, Inc. (Nasdaq: XENT) announced the initiation of the EXPAND Clinical Study, registered on ClinicalTrials.gov. This study will evaluate the efficacy of the PROPEL Contour sinus implant combined with balloon sinus dilation in treating chronic rhinosinusitis. Enrolling approximately 80 patients, results are anticipated by 2022. The trial aims to enhance procedural growth and assess clinical benefits, potentially supporting future label expansions.

Intersect ENT (Nasdaq: XENT) announced it will release its first quarter 2021 financial results on May 4, 2021, at approximately 7:00 a.m. ET. A conference call will be held at 8:30 a.m. ET to discuss these results. The Company focuses on transforming patient care through its innovative medical technology for ENT. Intersect ENT has expanded its product portfolio through its acquisition of Fiagon AG Medical Technologies, enhancing its offerings in the sinus implant market.

Intersect ENT (Nasdaq: XENT) announced the resignation of Anthony Vernon from its Board of Directors effective March 31, 2021, after six years of service. His departure is to pursue other interests. Elisabeth Sandoval-Little has been appointed to the Board, bringing over 30 years of experience in the biopharmaceutical industry. She is expected to enhance the company's strategy and growth. Intersect ENT focuses on innovative ENT medical technologies and recently expanded its portfolio through the acquisition of Fiagon AG. This leadership change may positively influence the company's direction and market presence.

Intersect ENT, Inc. (Nasdaq: XENT) has appointed Neil Hattangadi, M.D., M.Sc. to its Board of Directors, where he will serve on the Nominating and Corporate Governance Committee. Hattangadi, known for his entrepreneurial success in the ENT field, aims to enhance the company's product offerings, particularly in localized drug delivery for rhinosinusitis. President and CEO Thomas A. West expressed enthusiasm about Hattangadi's potential contributions. Intersect ENT is focused on advancing its innovative ENT medical technologies and broadening access to effective care.

Intersect ENT, a leader in ENT medical technology, announced that its CEO Tom West and CFO Randy Meier will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 2:30 p.m. ET. Investors can access the webcast via the company’s Investor Relations page. The event will highlight the company's efforts to expand its innovative treatment solutions, particularly following its acquisition of Fiagon AG Medical Technologies. Intersect ENT continues to enhance patient care with its unique steroid-releasing implants.

Intersect ENT, Inc. (XENT) reported Q4 2020 revenue of $28.2 million, down from $31.8 million in Q4 2019, partially offset by a record $2.6 million from SINUVA and $0.9 million from the Fiagon portfolio. The net loss widened to $20.2 million, or $0.62 per share, compared to $8.0 million in Q4 2019. Full-year 2020 revenue declined to $80.6 million from $109.1 million in 2019. However, the company anticipates revenue growth in 2021, projecting $116 million - $120 million, supported by increased elective procedure volumes and improved product access.